Remdesivir-induced Bradycardia is not Associated with Worse Outcome in Patients with COVID-19: A Retrospective Analysis.
Ioannis PantazopoulosGeorgios MavrovounisGeorgios DimeasNikolaos ZikosMaria PitsikouEleni RousogianniMaria MermiriAnastasia MichouMichalis SpanosChristos ManiotisAthanasios ChalkiasEleni LaouGeorgios ZakynthinosDimitrios ChatzisKonstantinos GourgoulianisPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2022)
Treatment with remdesivir may be associated with new-onset bradycardia in hospitalised patients with COVID-19. However, bradycardia is transient and is not associated with ICU admission and mortality.
Keyphrases
- emergency department
- intensive care unit
- high glucose
- diabetic rats
- cardiovascular events
- risk factors
- mechanical ventilation
- drug induced
- cerebral ischemia
- oxidative stress
- combination therapy
- coronary artery disease
- endothelial cells
- brain injury
- subarachnoid hemorrhage
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- community acquired pneumonia